On this episode of Investor Connect, Hall welcomes PPaola Torre, venture partner at Acquilus Ventures and board member at Life Science Angels. Located in the United States, Life Science Angels invests exclusively in early-stage life sciences companies at the seed and early Series A stages, combining capital with deep operational, scientific, and clinical expertise and hands-on mentoring beyond the check. The group emphasizes translational credibility, unmet medical need, team quality, and risk management, pressure-testing IP, regulatory strategy, and timelines, and increasingly values pharma partnerships as predictive for 2026; it also collaborates through syndicates with other angels, VCs, and strategics.

Paola is a PhD scientist with hands-on R&D experience at BioMarin Pharmaceutical across fibrosis, neurometabolic disorders, and cardiovascular disease, and she works at the intersection of biotechnology, venture capital, and healthcare innovation. She shares LSA's approach to deal structures and valuation discipline (including a $15M pre-money cap and use of convertible notes), how angels help de-risk capital-intensive biotech, what makes founders successful, and her views on next-generation therapies, AI-enabled platforms, non-animal models, and AI risks, standards, and FDA priorities.

Visit www.lifescienceangels.com

Reach out to at www.linkedin.com/in/paola-torre-phd/?locale=en_US

________________________________________________________________________

For more episodes from Investor Connect, please visit the site at: http://investorconnect.org

Check out our other podcasts here: https://investorconnect.org/
For Investors check out: https://tencapital.group/investor-landing/
For Startups check out: https://tencapital.group/company-landing/
For eGuides check out: https:/_/tencapital.group/education/
For upcoming Events, check out https://tencapital.group/events/

For Feedback please contact info@tencapital.group

Please follow, share, and leave a review.

Music courtesy of Bensound.